CSPHF:OTC-CStone Pharmaceuticals (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.12

Change

0.00 (0.00)%

Market Cap

USD 0.18B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

N/A

USD 598.54B
CSLLY CSL Ltd

N/A

USD 91.15B
CMXHF CSL Limited

N/A

USD 88.48B
UCBJF UCB SA

N/A

USD 26.91B
UCBJY UCB SA ADR

N/A

USD 26.37B
ARGNF argenx SE

N/A

USD 22.41B
GNMSF Genmab A/S

N/A

USD 17.89B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 6.87B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.83B
REGMF RemeGen Co. Ltd

N/A

USD 6.81B

ETFs Containing CSPHF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -62.62% 14% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.62% 15% F 6% D-
Trailing 12 Months  
Capital Gain -74.47% 22% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -74.47% 22% F 11% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 9,734.98% 98% N/A 99% N/A
Dividend Return 9,734.98% 98% N/A 99% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A 2% F 1% F
Risk Adjusted Return 8.71% 57% F 43% F
Market Capitalization 0.18B 79% B- 60% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.